JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature.

Objectives: JAK kinase inhibitors (JAKi) are a new therapeutic option in the treatment of rheumatoid arthritis, but they are not without risks, especially the incidence of herpes zoster (HZ).

Material And Methods: Systematic literature review that evaluates the incidence of HZ published in the clinical trials of the different JAK is marketed or under study.

Results: The HZ rates ranged between 1.